AHA 2023: get the interventional cardiology perspective!

Condensed take-home messages from the American Heart Association Scientific Sessions 2023

Stay up to date with what is new and hot in interventional cardiology at #AHA23 in Philadelphia.

Reviews & exclusive interviews

Aaysha Cader and Luis Ortega Paz provide their take on a selection of major late-breaking trials and studies of interest to the interventional cardiology community presented at AHA 2023!

ORBITA-2 - Percutaneous coronary intervention for stable angina: A randomized, placebo-controlled trial
DAPA-MI - A registry-based randomized trial of dapagliflozin in patient with acute myocardial infarction without diabetes
Half-dose tenecteplase or primary PCI in older patients with ST-elevation myocardial infarction: The STREAM-2 1-year mortality follow-up results